Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2004 Jan;57(1):86-92.
doi: 10.1046/j.1365-2125.2003.01953.x.

Differences between clinical trials and postmarketing use

Karin Martin  1 , Bernard Bégaud, Philippe Latry, Ghada Miremont-Salamé, Annie Fourrier, Nicholas Moore
Affiliations
Comparative Study

Differences between clinical trials and postmarketing use

Karin Martin et al. Br J Clin Pharmacol. 2004 Jan.

Abstract

Aims: Clinical trials constitute the gold standard to assess the efficacy and safety of new medicines. However, because they are conducted in standardized conditions far from the real world of prescription and use, discrepancies in patient selection or treatment conditions may alter both the effectiveness and risks. On the basis of three examples, our objectives were to study the differences between the characteristics of treated populations and treatment patterns in clinical trials and in postmarketing settings and to discuss the potential consequences on actual efficacy and safety.

Methods: Treated populations were compared with patients included in premarketing clinical trials. Comparisons were made on the basis of demographic characteristics and treatment patterns.

Results: Whatever the indicator and the drug studied, differences were observed: from 0.04% to 63% for tacrine, from 0% to 37% for celecoxib and from 6% to 52% for simvastatin, with possible consequences on the effectiveness and safety of the drug concerned. Our results confirm the under-representation of women and elderly patients in premarketing clinical trials, e.g. an M : F ratio of 4.6 in clinical trails of simvastatin vs 1.0 in the joint population. Moreover, the concomitant use of medicines was made extremely restrictive by the protocols of these trials while this was not the case in the postmarketing phase. This has possible consequences on the effectiveness and safety of the drug concerned.

Conclusions: These results plead for systematic ad hoc observational postmarketing studies for any novel and/or expensive medicine to assess the relevance of premarketing data.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Age distribution for the three populations for celecoxib. Target population (▪), joint population (formula image) and injured population (□).
Figure 2
Figure 2
Age distribution for the three populations for simvastatin. Target population (▪), joint population (formula image) and injured population (□).
See this image and copyright information in PMC

References

    1. Pablos-Méndez A, Barr G, Shea S. Run-in periods in randomized trials. Implications for the application of results in clinical practice. JAMA. 1998;279:222–225. - PubMed
    1. Black N. Why we need observational studies to evaluate the effectiveness of health care. Br Med J. 1996;312:1215–1218. - PMC - PubMed
    1. Hemminki E. Problems of clinical trials as evidence of therapeutic effectiveness. Soc Sci Med. 1982;16:711–712. - PubMed
    1. Ray WA, Griffin MR. Evaluating drugs after their approval for clinical use. N Engl J Med. 1993;329:2029–2032. - PubMed
    1. Jaillon P, Girard M, Ponsonnaille J. Tolérance électrocardiographique du bépridil (cordium) La Lettre Du Pharmacologue. 1991;5:202–206.

Publication types